“We take care of you, so you can take care of your patients.” For more than three decades, AMS Solutions has handled medical billing for neurology and neurosurgery practices across the United States. We’re U.S.-based, in-house, AAPC-certified, and HIPAA-compliant — and we know neurology coding inside and out, from EMG/NCS pro-tech splits to chronic migraine injection to neurology’s notoriously high denial rate (35% initial, 14-18% chronic, the highest of any specialty). This page walks through how AMS handles neurology billing, the procedures and modifiers we work with daily, and what to expect when you partner with us.
Every AMS client is assigned a dedicated billing team led by an Account Manager you can reach directly — no overseas call centers, no phone trees, no handoffs between strangers. Your team is built specifically for neurology coding nuances and the EMR/EHR you already use (Epic, NextGen, eClinicalWorks, athenahealth, and others).
Neurology has the highest claim denial rate of any specialty — 35% initial, 14–18% chronic. The reasons are structural: pro/tech component splits on EMG and EEG, dense modifier rules around E&M-with-procedure bundling, payer-specific prior authorization on chronic migraine injections and infusion drugs, and ongoing LCD compliance pressure. We have specific operational depth in each.
EMG/NCS is the highest-volume neurology procedure, and the professional vs. technical component split (modifier -26 and -TC) is where most claims get denied. Key codes we work daily:
Long-term and ambulatory EEG monitoring has expanded under newer CPT codes, and payers are aggressive about technical-component documentation:
OnabotulinumtoxinA for chronic migraine is one of the most denial-prone procedures in neurology because of (1) PA requirements with payer-specific clinical criteria, (2) the J-code drug bill that often gets miscoded as the procedure code, and (3) the strict 12-week interval requirement:
IVIG, anti-CD20 monoclonal antibodies, natalizumab,, and other infused biologics for MS, myasthenia gravis, and CIDP carry both high reimbursement and high denial risk. We handle:
Neurology PAs cover OnabotulinumtoxinA, infusions, advanced imaging (MRI brain with contrast, MRI spine), implanted devices (DBS, VNS, RNS), and selected EMG/NCS combinations. We submit and track PAs as part of the same workflow that submits the claim — not as an afterthought — with payer-specific submission rules we update each quarter.
A neurology practice with $250,000 in monthly collections and a 14% chronic denial rate is leaving roughly $35,000 on the table every month. Cut that denial rate to 7% — realistic when EMG/NCS modifier splits are enforced, OnabotulinumtoxinA PAs are tracked alongside the procedure, and infusion J-code units are reconciled to the drug ordered — and you recover roughly $17,500 a month. That’s $210,000 a year in revenue that was already yours. Example for illustration purposes only. Actual results vary by specialty, payer mix, volume, workflow, and current billing performance.
We work the full neurology code set every day — including EMG/NCS 95860-95913, EEG 95812-95830, sleep studies 95805-95811, evoked potentials 95925-95930, autonomic function testing 95921-95924, lumbar puncture 62270, and the chronic migraine injection J0585 injections (64615) family. Our coders know which procedures bundle, which modifiers are required, and how each payer handles pro/tech splits.
EMG and nerve conduction studies routinely split between professional (modifier 26) and technical (TC) components, and the rules differ by place of service and equipment ownership. We track who’s reading the study, who owns the equipment, and bill professional vs. global vs. technical accordingly. We also ensure the correct CPT pairing — e.g. 95910 vs. 95911 vs. 95912 based on nerve count — because miscoding this is one of the most common sources of neurology underpayment.
Yes. Chronic migraine OnabotulinumtoxinA is one of the most prior-auth-intensive billable services in neurology. We handle the J0585 unit dosing (typically 155-195 units), the 64615 administration code, the required prior auth and step therapy documentation, and the 12-week re-auth cycle. We also track and recover NDC pricing and J&J/AbbVie copay assistance where applicable.
Neurology has one of the highest prior auth burdens in medicine — OnabotulinumtoxinA, MRI/MRA, IVIG, monoclonal antibodies for migraine (CGRP), and many EP and sleep studies require auth. We track each payer’s requirements, file the request with supporting clinical, follow up until you have a number, and confirm the auth is attached to the claim before submission. Missed auths drive roughly 15-18% of neurology denials when not actively managed.
Neurology has the highest initial denial rate of any specialty (35% initial, 18% chronic). Denials are worked the day they hit your aging, not weekly. We root-cause each denial — auth, eligibility, LCD/NCD policy, modifier, documentation — appeal the winnable ones, and report trends back monthly so the same denial pattern stops repeating. Most clients see their denial rate drop materially within 90 days.
Most neurology clients are fully onboarded inside 2-4 weeks. We handle the EHR/PM integration (Epic, NextGen, eClinicalWorks, athenahealth, and others), payer setup, fee schedule load, and provider enrollment review. Your practice keeps seeing patients without disruption during the transition.
AMS Solutions provides specialty-specific medical billing across neurology and the practices that share neurology’s prior auth complexity and high denial environment. Explore our other specialty billing pages:
We bill across the full neurology code set, including EMG and nerve conduction studies (CPT 95860–95887 and 95907–95913), routine and long-term EEG (CPT 95812–95819 and 95700–95726), OnabotulinumtoxinA for chronic migraine (CPT 64615 + J0585), neurology infusion therapy (CPT 96365–96368 with J-codes for IVIG, anti-CD20 monoclonal antibodies, natalizumab,), and the modifier work that drives most neurology denials — modifier -25 for same-day E&M, modifier -26/-TC for pro-tech splits, and -59/X{EPSU} for distinct procedural services.
Neurology has the highest claim denial rate of any specialty (35% initial, 14–18% chronic). The structural reasons are EMG/EEG pro-tech component confusion, OnabotulinumtoxinA PA gaps, infusion J-code unit miscalculation, and modifier -25 vs -59 errors at the scrubbing layer. Most of our neurology clients move from a 14–18% chronic denial rate to 7–9% within the first 90 days by addressing these specific patterns.
OnabotulinumtoxinA for chronic migraine almost universally requires PA, and payer-specific clinical criteria (failed step therapy, headache day frequency, prior preventive trials) vary widely. We submit and track OnabotulinumtoxinA PAs as part of the same workflow that schedules and bills the injection, with a 12-week interval reminder so re-dose claims are submitted on time and not after the patient is non-compliant on paper.
Yes. AMS operates under signed Business Associate Agreements (BAAs) with every client practice. We use encrypted data transfer, secure networks, and role-based access controls. Our team is trained annually on HIPAA requirements.
We offer a free practice audit. Send us your aging A/R, three months of receivables, and three months of billables. We return a written assessment of your clean claim rate, denial breakdown by category, days in AR by payer, and the specific revenue we believe is recoverable. No commitment, no obligation.
If you’re considering switching billing partners — or moving from in-house to outsourced for the first time — we offer a free practice audit. Within two weeks you’ll receive a written report covering your clean claim rate, denial breakdown by category, days in AR by payer, and the specific revenue we believe is recoverable. The audit is yours whether you hire us or not.
EEG, EMG/NCS, OnabotulinumtoxinA for chronic migraine, and the prior-auth gauntlet codes neurology billing teams need at their fingertips. Save it for your team.
Download the Cheat SheetFree Consultation
Schedule Meeting